A Novel Laboratory-Scale Pneumatic Tube System (PTS) Transportation Model to Assess the Impact of Hospital PTS Transportation on the Product Quality of Therapeutic Monoclonal Antibodies.

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Kashappa Goud Desai, James D Colandene, Cait Sofa, Nathan Heacock, Ning Wang, Bivash Mandal, Brendan Blockus, Shin Lu
{"title":"A Novel Laboratory-Scale Pneumatic Tube System (PTS) Transportation Model to Assess the Impact of Hospital PTS Transportation on the Product Quality of Therapeutic Monoclonal Antibodies.","authors":"Kashappa Goud Desai, James D Colandene, Cait Sofa, Nathan Heacock, Ning Wang, Bivash Mandal, Brendan Blockus, Shin Lu","doi":"10.1021/acs.molpharmaceut.5c00428","DOIUrl":null,"url":null,"abstract":"<p><p>The rapid and efficient transportation of therapeutic monoclonal antibody (mAb) dosing solutions, prepared in intravenous (IV) infusion containers (e.g., IV bags), from pharmacy departments to target locations within hospital campuses globally requires the use of pneumatic tube systems (PTSs). Evaluating the impact of hospital pneumatic tube system (PTS) transportation on the quality attributes of mAb dosing solutions poses significant challenges for pharmaceutical companies. Herein, we present a novel, first-of-its-kind laboratory-scale PTS transportation model capable of assessing the effects of hospital PTS transportation on the product quality of therapeutic mAbs. The laboratory-scale PTS transportation model generated shock and vibration stresses comparable to those experienced in a model hospital PTS transportation. The impact on the product quality of a test mAb due to model hospital PTS transportation was comparable to that observed with laboratory-scale PTS transportation. We found that the impact of PTS transportation on product quality was influenced by the cumulative stress levels experienced by the mAb. Additionally, the product quality was affected by the type of surfactant. The effectiveness of removing air headspace from an IV bag prior to PTS transportation, as a means to mitigate the product quality impact, was also influenced by cumulative PTS stress levels. PTS transportation, with or without stabilizing surfactant in the dosing solution, did not negatively affect the conformational stability, the tertiary structure, or the potency of the test mAb. This study demonstrates a practical approach for designing laboratory-scale PTS transportation studies to assess the risk to product quality of a given mAb due to hospital PTS transportation, determine the residual surfactant (e.g., polysorbate 80/PS80) level needed for protein stabilization, and establish safe transportation and handling practices when using hospital PTS systems.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.molpharmaceut.5c00428","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

The rapid and efficient transportation of therapeutic monoclonal antibody (mAb) dosing solutions, prepared in intravenous (IV) infusion containers (e.g., IV bags), from pharmacy departments to target locations within hospital campuses globally requires the use of pneumatic tube systems (PTSs). Evaluating the impact of hospital pneumatic tube system (PTS) transportation on the quality attributes of mAb dosing solutions poses significant challenges for pharmaceutical companies. Herein, we present a novel, first-of-its-kind laboratory-scale PTS transportation model capable of assessing the effects of hospital PTS transportation on the product quality of therapeutic mAbs. The laboratory-scale PTS transportation model generated shock and vibration stresses comparable to those experienced in a model hospital PTS transportation. The impact on the product quality of a test mAb due to model hospital PTS transportation was comparable to that observed with laboratory-scale PTS transportation. We found that the impact of PTS transportation on product quality was influenced by the cumulative stress levels experienced by the mAb. Additionally, the product quality was affected by the type of surfactant. The effectiveness of removing air headspace from an IV bag prior to PTS transportation, as a means to mitigate the product quality impact, was also influenced by cumulative PTS stress levels. PTS transportation, with or without stabilizing surfactant in the dosing solution, did not negatively affect the conformational stability, the tertiary structure, or the potency of the test mAb. This study demonstrates a practical approach for designing laboratory-scale PTS transportation studies to assess the risk to product quality of a given mAb due to hospital PTS transportation, determine the residual surfactant (e.g., polysorbate 80/PS80) level needed for protein stabilization, and establish safe transportation and handling practices when using hospital PTS systems.

一种新型实验室规模气动管系统(PTS)运输模型评估医院PTS运输对治疗性单克隆抗体产品质量的影响
在静脉(IV)输液容器(例如,静脉输液袋)中制备的治疗性单克隆抗体(mAb)给药溶液从药剂科快速有效地运输到全球医院校园内的目标地点,需要使用气动管系统(ppts)。评估医院气动管道系统(PTS)运输对单抗给药解决方案质量属性的影响对制药公司提出了重大挑战。在此,我们提出了一种新颖的、首创的实验室规模PTS运输模型,能够评估医院PTS运输对治疗性单克隆抗体产品质量的影响。实验室规模PTS运输模型产生的冲击和振动应力与医院PTS运输模型所经历的应力相当。模型医院PTS运输对测试单抗产品质量的影响与实验室规模PTS运输所观察到的影响相当。我们发现PTS运输对产品质量的影响受到单抗所经历的累积应激水平的影响。此外,表面活性剂的种类对产品质量也有影响。作为减轻产品质量影响的一种手段,在PTS运输之前从静脉输液袋中去除空气顶空的有效性也受到PTS累积压力水平的影响。在给药溶液中加入或不加入稳定表面活性剂,PTS转运都不会对单克隆抗体的构象稳定性、三级结构或效力产生负面影响。本研究展示了一种设计实验室规模PTS运输研究的实用方法,以评估由于医院PTS运输对给定单抗产品质量的风险,确定蛋白质稳定所需的残余表面活性剂(例如聚山梨酯80/PS80)水平,并在使用医院PTS系统时建立安全运输和处理实践。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信